US-based, New York-listed pharma AbbVie has announced its entrance into the obesity field with a licensing agreement with Denmark-based, Copenhagen-listed Gubra to develop GUB014295, a potential best-in-class, long-acting amylin analog…
Denmark: Abbvie enters obesity field with license agreement with Gubra
…
…






